In a recent interview with Diagnostic Imaging, Eliad Josephson discussed key attributes of the HLTH USA conference, AI trends and an ongoing shift of emphasis on the development of predictive technologies with diagnostics at center stage.

In a recent interview, Francesco Giganti, MD, PhD, discussed findings from a recent multicenter study demonstrating the ability of an AI software to provide significant clarity to initial PI-RADS 3 assessments on MRI and facilitate a nearly 19 percent reduction in unnecessary prostate biopsies.

In a recent interview, Phillip Koo, MD, discussed emerging trends with AI, theranostics and empowered patients, and how these developments may lead to challenges and potential opportunities for radiologists and nuclear medicine physicians.

An AI model for prostate MRI offered an 89 percent AUC for prostate cancer detection in external validation testing, according to a newly published international multicenter study.

In a recent episode of our Molecular Imaging in Focus series, Jack Andrews, MD, discussed pertinent findings from a recent intra-patient comparative study of PSMA PET agents in men with recurrent prostate cancer presented at the recent ASTRO conference.

How will generative AI software be evaluated by the FDA in the future? What’s next for point-of-care ultrasound? What steps have been successful in facilitating adoption of AI applications across enterprise systems? Leaders in radiology and health care will be discussing these topics and more at the upcoming HLTH USA conference.

Catch up on the top radiology content of the past week.

Emerging CT research suggests that the plexus pancreaticus capitalis 2 (PPC2) pathway or a mass with stranding morphology may significantly increase mortality risk in patients with pancreatic cancer and extra-pancreatic nerve plexus invasion (EPNI).